Reinstating endogenous antitumor immunity: The concept of therapeutic management of cancer
, oraz
17 wrz 2016
O artykule
Kategoria artykułu: Research Article
Data publikacji: 17 wrz 2016
Zakres stron: 4 - 16
Otrzymano: 24 lut 2016
Przyjęty: 04 sie 2016
DOI: https://doi.org/10.1515/fco-2016-0005
Słowa kluczowe
© 2016
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Strong evidence points to the role of cancer immunoediting and tumor immune infiltrates in regulating cancer progression. By understanding the immune tumor microenvironment, we can now target key pathways that suppress endogenous antitumor responses, thereby re-instating such immune responses and identifying novel targets for immune therapies. Therapies targeting oncogenic pathways and checkpoint blockades turn on a new paradigm shift in immune-therapy for cancer with remarkable clinical efficacy seen in various malignancies. However, a lot of cancer patients will fail to respond and therefore, it becomes crucial to identify biomarkers to predict who of the patients will most likely benefit from these therapies.